Autolus Therapeutics Reports Q1 2026 Financial Results and Business Updates
LONDON and GAITHERSBURG, Md., May 14, 2026 – Autolus Therapeutics plc (Nasdaq: AUTL), a commercial-stage biopharmaceutical company focused on the development of next-generation programmed T cell therapies, has announced its financial results and operational updates for the first quarter ended March 31, 2026.
Key Financial and Operational Highlights
- AUCATZYL® (obecabtagene autoleucel; obe-cel) net product revenue reached \$26.2 million in Q1 2026, a significant increase from \$9.0 million in Q1 2025, reflecting robust launches in both the US and the UK.
- The company achieved a positive gross margin for its ALL (acute lymphoblastic leukemia) business for the first time, marking a pivotal shift towards profitability.
- A major cost reduction initiative was announced, aiming to further improve gross profit margins and operational efficiency, with an anticipated annualized reduction in operating expenses of approximately \$15 million beginning in 2027. This includes a workforce reduction of about 13% across all business areas.
- Clinical development programs for obe-cel are advancing in lupus nephritis, pediatric ALL, and progressive multiple sclerosis (MS), with pivotal and early-stage trials ongoing in each indication.
- Autolus reiterates its full-year 2026 revenue guidance for AUCATZYL of \$120–\$135 million, a significant increase from \$74 million in 2025, and expects continued positive gross margin.
- The company’s cash, cash equivalents, and marketable securities stood at \$229.4 million as of March 31, 2026, expected to be sufficient to fund operations into Q4 2027.
Business Updates and Shareholder-Relevant Developments
AUCATZYL® Commercial Performance and Market Expansion
- Strong performance in the US market, with expanding physician adoption in adult ALL driven by consistent product delivery and high-quality outcomes.
- The UK launch, initiated in January 2026, is off to a promising start, with routine commissioning now in place.
- Real-world data from the ROCCA consortium (covering about 60% of US commercial patients) confirms the safety and efficacy profile seen in the pivotal FELIX trial, supporting further market confidence and potential expansion.
- AUCATZYL® received FDA approval in November 2024 for adult r/r B-cell precursor ALL and conditional marketing authorizations in the UK and EU in 2025.
Pipeline and Clinical Development
- CATULUS (Pediatric r/r B-ALL): Phase 2 portion is underway, with data expected by year-end 2027. Obe-cel holds RMAT (Regenerative Medicine Advanced Therapy) designation from the FDA for this population.
- LUMINA (Lupus Nephritis): Pivotal Phase 2 trial is enrolling, following positive FDA alignment on a registrational pathway. Data anticipated in 2028.
- BOBCAT (Progressive MS): Phase 1 trial is enrolling up to 18 adult patients, with initial data expected by year-end 2026 and full data in 2027.
- ALARIC (Light-Chain Amyloidosis): Phase 1 trial for AUTO8 is ongoing, with initial data also expected by year-end 2026.
Strategic Cost Reductions and Restructuring
- In April 2026, Autolus announced a strategic initiative to improve efficiency, including a reduction in force impacting 13% of staff, expected to reduce annual operating expenses by \$15 million from 2027.
- Restructuring charges are estimated at \$8 million, mainly related to employee severance, to be recognized primarily in the first half of 2026. The restructuring is expected to be largely complete by Q3 2026.
Financial Performance Summary
- Net product revenue: \$26.2 million in Q1 2026 (vs. \$9.0 million in Q1 2025)
- Cost of sales: \$24.6 million (vs. \$18.0 million in Q1 2025), reflecting higher sales volume and inventory management costs
- Gross profit: \$1.6 million – first positive gross profit in company history
- R&D expenses: Decreased to \$21.2 million (from \$26.7 million), due to lower clinical trial and manufacturing supply costs
- Selling, general & administrative (SG&A) expenses: Increased to \$39.9 million (from \$29.5 million), driven by commercialization investments and one-time termination-related costs
- Loss from operations: \$59.5 million (improved from \$65.2 million in Q1 2025)
- Net loss: \$71.6 million (compared to \$70.2 million in Q1 2025)
- Cash, cash equivalents, and marketable securities: \$229.4 million as of March 31, 2026 (down from \$300.7 million at year-end 2025)
Upcoming Catalysts and Anticipated News Flow
- By year-end 2026:
- Long-term follow-up data from CARLYSLE trial (systemic lupus erythematosus)
- Initial clinical data from BOBCAT (progressive MS) and ALARIC (light-chain amyloidosis) Phase 1 trials
- In 2027:
- Full data from BOBCAT trial (progressive MS)
- Phase 2 data from CATULUS (pediatric r/r B-ALL)
- In 2028:
- Phase 2 data from LUMINA (lupus nephritis)
Product Safety and Regulatory Information
- AUCATZYL® (obe-cel) is a CD19-directed CAR T cell therapy approved for adult r/r B-cell precursor ALL. It is designed to minimize excessive T cell activation and improve safety/efficacy versus earlier CAR T therapies.
- Important safety concerns: Cytokine release syndrome (CRS) in 75% of patients, neurological toxicities (ICANS) in 64%, prolonged cytopenias, severe infections, hypogammaglobulinemia, hemophagocytic lymphohistiocytosis/macrophage activation syndrome (HLH/MAS), hypersensitivity reactions, and secondary malignancies have been observed.
- Fatal adverse reactions occurred in 9% of patients, most commonly due to infections, and are associated with pre-existing or therapy-induced neutropenia.
- Healthcare providers must follow stringent monitoring and management protocols for CRS, ICANS, and other AEs.
Shareholder-Relevant, Price-Sensitive Information
- First positive gross margin achieved in the ALL business, marking a key milestone toward profitability. This could significantly affect investor sentiment and share price.
- Major cost reduction and restructuring program announced, expected to improve the company’s path to profitability and free up capital for growth. This includes a 13% workforce reduction and anticipated \$15 million annualized savings starting in 2027.
- Strong commercial growth for AUCATZYL® in the US and UK, with guidance for \$120–\$135 million in net product revenue for 2026, up from \$74 million in 2025.
- Multiple upcoming clinical data readouts in high-value indications (autoimmune and hematological) through 2026–2028, which could serve as significant price-moving catalysts.
- Cash runway into Q4 2027 provides near-term financial stability, reducing dilution risk and supporting continued R&D investment.
Conclusion
Autolus Therapeutics delivered a strong start to 2026, with record product revenues, a milestone positive gross margin, and a clear strategy for operational efficiency and future growth. The ongoing launches of AUCATZYL® in the US and UK, alongside a robust clinical pipeline in both hematological and autoimmune diseases, position the company for further value creation. The announced cost reduction and restructuring initiatives are expected to accelerate the path to profitability and enhance shareholder value.
Investors should closely monitor: progress on commercial execution, upcoming clinical milestones across the pipeline, cost management, and cash runway developments. These factors, in combination with a first-ever positive gross margin and strong revenue guidance, are all likely to influence Autolus’ share price in the near and medium term.
Disclaimer: This article is for informational purposes only and is not intended as investment advice. Investors should conduct their own due diligence and consult with their financial advisors before making investment decisions. The information herein is based on publicly available company disclosures as of May 14, 2026. Forward-looking statements are subject to risks and uncertainties as described by the company in its SEC filings.
